Suven Life Sciences Limited announced its Un-audited financial results for the quarter ended 31st December 2018.
HYDERABAD, INDIA (5th February 2019) – Suven Life Sciences Limited, a biopharmaceutical company specialized in CRAMS for global life science companies and drug discovery and developmental activities in Central Nervous System disorders, today announced its Un-audited financial results for the quarter ended 31st December 2018. The Un-audited financial results were reviewed by the audit committee and approved by the Board of Directors in their meeting held on 5th Feb’ 2019 at Hyderabad
Financial Highlights for the 3rd Quarter ended December’ 2018 (QoQ):
Growth in income - INR 1348 Mn vs 961 Mn - up by 40.24%
Growth in PAT - INR 252 Mn vs 179 Mn - up by 40.27%
Growth in EBIDTA - INR 413 Mn vs 310 Mn - up by 33.41%
Financial Highlights for the 9 months’ period ended December’ 2018 (YoY):
Growth in income - INR 4307 Mn vs 4256 Mn - up by 1.20%
Growth in PAT - INR 819 Mn vs. 958 Mn - down by 14.57%
Growth in EBIDTA - INR 1387 Mn vs 1557 Mn - down by 10.92%
Suven’s expenses on innovative R&D in Drug Discovery stood at INR 424 Mn (9.85% on revenue) for the 9 months’ period ended Dec’ 2018.
The Board has declared an Interim Dividend of Re.1.50 per share (150% of face value of Rs. 1.00 each).
Suven Board approved of demerger of Contract Research and Manufacturing Services undertaking of Suven Life Sciences Limited (SLSL) into Suven Pharmaceuticals Limited (SPL), through a scheme of arrangement, subject to approval of respective regulatory authorities. More details will be notified separately.
For more information on Suven please visit our Web site at http://www.suven.com
Risk Statement:
Except for historical information, all of the statements, expectations and assumptions, including expectations and assumptions contained in this news release may be forward-looking statements that involve a number of risks and uncertainties. Although Suven attempts to be accurate in making these forward-looking statements, it is possible that future circumstances might differ from the assumptions on which such statements are based. Other important factors which could cause results to differ materially including outsourcing trends, economic conditions, dependence on collaborative programs, retention of key personnel, technological advances and continued success in growth of sales that may make our products/services offerings less competitive; Suven may not undertake to update any forward-looking statements that may be made from time to time.
Suven Life Sciences Limited
Registered Office: 8-2-334 I SDE Serene Chambers I 6th Floor, Road No.5 I Avenue 7 Banjara Hills I Hyderabad – 500 034 I Telangana I India I CIN: L24110TG1989PLC009713
Tel: 91 40 2354 1142/ 3311/ 3315 Fax: 91 40 2354 1152 Email: info@suven.com website: www.suven.com
